Inside Precision Medicine August 5, 2024
Ideaya Biosciences is paying $400M+ for an option on Biocytogen Pharmaceuticals’ potential first-in-class B7H3/PTK7 BsADC program. Antibody drug conjugates (ADCs) combine the specificity of monoclonal antibodies with cytotoxic drugs aimed at delivering highly targeted treatment. Biocytogen says B7H3/PTK7 is co-expressed in multiple solid tumor types, including having double-digit percent prevalence in lung, colorectal, and head and neck cancers, among others.
Biocytogen leverages genetically engineered proprietary RenMice platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery.
One of the most competitive fields in pharma today, the ADC market is estimated to be worth almost $20B already. Fifteen ADCs have already been FDA approved.The three front-runners in this field, Merck, AZ/Daiichi, and Gilead, have...
Today's Sponsors
Today's Sponsor